AbbVie (ABBV) and Simcere Zaiming said Monday they have entered an option-to-license agreement to develop a multiple myeloma bone marrow cancer treatment SIM0500.
SIM0500, which is currently undergoing phase 1 clinical trials, aims to treat patients with relapsed or refractory multiple myeloma in both China and the US, the companies said.
Under the agreement, AbbVie will pay Simcere Zaiming an upfront amount along with additional option fees and milestone payments for a total of up to $1.06 billion, they added.
Simcere Zaiming will receive tiered royalties on net sales outside Greater China, while AbbVie will get tiered royalties in Greater China, according to the companies.
Shares of AbbVie were up 1.3% in recent trading
Price: 177.50, Change: +2.33, Percent Change: +1.33
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。